secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2022-03-01T23:59:59+00:00
Accession:  0001564590-22-008030
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax reports Q4 net profit of $96.2M from Incyte deal; names new CMO
----------------------------------------------------------------------

- Net profit $96.2M ($1.81/sh) vs loss $20.4M prior Q; revenue $126.6M from Incyte collaboration.
- Cash $439.9M at Dec 31; FY2022 R&D guidance $130-140M, total opex $160-170M.
- Kate Madigan appointed CMO effective March 1, succeeding Michael Meyers who retires.
- Pivotal trials for SNDX-5613 and axatilimab enrollment on track; topline data expected 1H2023, potential NDA/BLA filing 2023.
- Three new trials of SNDX-5613 expected to initiate 1H2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000156459022008030/0001564590-22-008030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000156459022008030/sndx-8k_20220301.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-008030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer